Buy this Article for $3.95

Have a coupon or promotional code? Enter it here:

When you buy this you'll get access to the ePub version, a downloadable PDF, and the ability to print the full article.

Authors

  1. Aschenbrenner, Diane S. MS, RN

Abstract

* Elotuzumab (Empliciti) is a new monoclonal antibody approved to treat multiple myeloma in combination with lenalidomide (Revlimid) and dexamethasone.

 

* Use is restricted to patients who have already received one to three drug therapies to treat the condition.

 

* Elotuzumab commonly produces infusion reactions, and premedication is necessary. Patients may also develop second primary malignancies or hepatotoxicity. Response to the drug can be difficult to measure.